Professor

Martin Post

Department of Paediatrics

PhD

Location
Hospital for Sick Children (SickKids)
Address
Peter Gilgan Centre for Research and Learning, 686 Bay St., Room 9.9705, Toronto, Ontario Canada M5G 0A4
Research Interests
Human Development & Aging, Molecular & Cell Biology
Appointment Status
Cross-Appointed

Dr Martin Post received his PhD from the University of Utrecht, The Netherlands, in 1982.

Following postdoctoral research training at Harvard Medical School, he was appointed as an Assistant Professor at Harvard in 1985.

This was followed by a move to The Hospital for Sick Children (SickKids) in 1986 where he is appointed as a Senior Scientist.

He served as Head of the Lung Biology (1998-2006) and Integrative Biology Programs (1999-2006) at SickKids and was named Program Head of  Physiology and Experimental Medicine in 2006.

Dr Post is also a Professor of Physiology and Pediatrics at the University of Toronto.

He directs the Centre for Study of Complex Childhood Diseases, a CFI-funded translational research initiative, supporting interventional studies in preclinical models and in patients.

He is also the Scientific Director of the Analytical Facility for Bioactive Molecules at Sickkids enabling metabolic research in Toronto and beyond.  

He holds a Canada Research Chair in Fetal, Neonatal and Maternal Health (2001-2022). His discovery research program focuses on lung development, injury and repair.

 

Research Synopsis

 

Preterm birth occurs in 5-10% of all pregnancies, leading to 75% of the early (neonatal) mortality and long-term disability (including cerebral palsy, deafness, blindness, mental and respiratory problems). 

One major complication associated with preterm birth is immaturity of the lung and, despite modern management, such as the use of surfactant and newer modes of neonatal ventilation; pulmonary immaturity remains a leading cause of neonatal morbidity and mortality. 

The aim of my research is to understand the biological and physiological mechanisms that direct lung development and the impact of preterm birth on this process.

The long term objective is to develop new therapeutic strategies, including lung regeneration, or to improve existing therapies.

Lung morphogenesis results from multiple interacting signaling pathways

Although great strides have been made in elucidating some of the signaling pathways that contribute to lung development there remain many gaps in our knowledge.

My long-term goal is to integrate the identified signaling pathways in a morphogenetic map, which can then be used to model aberrant lung development.

Mechanical ventilation is commonly used in neonatal respiratory failure, and is well known to cause -or worsen lung injury

In the neonate, developing lungs are still forming distal air exchange units: thus, mechanical ventilation can impair alveolar development by inhibiting lung cell growth, augmenting cell death and increasing inflammatory mediator expression.

We investigate the impact of ventilation (stretch) on lung cell fate in vitro and in vivo.

Emerging evidence suggests that stem cells can differentiate into lung cells

However, the environment and factors that are required for the differentiation of stem cells into lung-specific cells are largely unknown.

We are investigating the cellular commitment to a pulmonary phenotype and the potential of acellular lung scaffolds for tissue engineering.

A new exciting direction we explore is stem cell-based innate immune therapy using stem cell derived alveolar macrophages in pneumonia models. 

Sphingolipids are involved in the regulation of many cellular processes

Ceramides trigger cell death while sphingosine-1-phosphate (S1P) promotes cell survival. Thus, ceramides and S1P form a rheostat that balances apoptosis and proliferation; processes gone awry in the ventilated preterm lung.

Understanding and manipulation of the ceramide-S1P axis in the injured newborn lung may benefit its repair.

We are investigating sphingolipid metabolism in ventilated newborn animals and hyperoxia models of neonatal lung disease (i.e. BPD).

Lipidomics

Another line of investigation concerns lipidomics (large scale study of lipid quantity and function which may provide a molecular signature to a certain pathway or a disease condition). We perform lipidomic analysis to identify potential molecular lipid signatures in the tracheal fluid or sputum of (BPD, Asthma, COPD) patients as predictors and prognostic markers for outcomes.

We focus on wide screens for eicosanoids, sphingolipids (ceramides, sphingosines etc), phospholipids and lysophospholipids (PC.LPC,PE,PS, PI, PG etc), phosphatidic acids and oxidized lipids. 

Preeclampsia

Preterm birth can be due to preeclampsia, a complex and serious disorder of human pregnancy and the leading cause of fetal and maternal morbidity and mortality worldwide, affecting approximately 5-7% of all pregnancies.

Although, the etiology and pathophysiology of this disease remains an enigma, it is accepted that the presence of the placenta, not the fetus, is at the origin of this disease.

In collaboration with the Mother and Infant Research Group at Mt. Sinai Hospital, Toronto we investigate normal and abnormal placentation.

My Lab

My research group has state-of-the-art laboratory and office space on the 9th floor of the new SickKids research facility, the Peter Gilgan Centre for Research and Learning (PGCRL).  

The laboratory is fully equiped for molecular, cellular and physiologic research.

We have access to all SickKids core facilities providing crucial infrastructure, services and expert personnel to help us successfully deliver on our objectives, including:

  • Lab Animal Services
  • Embryonic Stem Cell Facility
  • TCP Transgenic Facility
  • Imaging Facility
  • Flow Cytometry Facility
  • primary access to the Analytical Facility of Bioactive Molecules specialized in metabolic research.

In addition, we have dedicated space within the animal facility for long term cardiopulmonary physiological studies. 

 

Recent Publications

 

Melland-Smith M, Ermini L, Chauvin S, Craig-Barnes H, Tagliaferro A, Todros T, Post M, Caniggia I. Disruption of Sphingolipid Metabolism Augments Ceramide-Induced Placental Autophagy in Preeclampsia. Autophagy. 2015 Apr 8:0. [Epub ahead of print].

Shojaie, S., Ermini, L., Ackerley, C., Wang, J., Chin, S., Yeganeh, B., Bilodeau,M., Sambi, M., Rogers, I., Rossant, J., Bear, CE., Post, M. Acellular Lung Scaffolds Direct Differentiation of Endoderm to Functional Airway Epithelial Cells: Requirement of Matrix-bound HS Proteoglycans. Stem Cell Reports 4: 1-12, 2015.

Kroon, A., Wang, J., Post, M. Alterations in Expression of Elastogenic and Angiogenic Genes by Different Conditions of Mechanical Ventilation in Newborn Rat Lung. Am J Physiol Lung Cell Mol Physiol. 308(7):L639-49, 2015.

Tibboel, J., Joza, S., Reiss, I., de Jongste, J., Post, M. Amelioration of hyperoxia-induced lung injury in newborn mice using a sphingolipid-based intervention. Eur Respir J.  42(3):776-784, 2013

Joza, S., Wang, J., Fox, E., Hillman, V., Ackerley, C., Post, M. Loss of Semaphorin-Neuropilin-1 signaling causes dysmorphic vascularization reminiscent of alveolar capillary dysplasia. Am. J. Pathol.181:2003-2017, 2012

 

Appointments

Program Head of  Physiology and Experimental Medicine, The Hospital for Sick Children (SickKids)
Scientific Director of the Analytical Facility for Bioactive Molecules, The Hospital for Sick Children (SickKids)

 

Honours and Awards

Name: Canada Research Chair in Fetal, Neonatal and Maternal Health (2001-2022)
Description: